How it should be taken
It comes as a solution to inject under the skin (subcutaneous), by a healthcare provider.
Dosage & When it is to be taken
SC- The recommended dose is 40mg to 80 mg, every two weeks; it may be increased if needed.
Juvenile Idiopathic Arthritis- 15 kg (33 lbs) to <30 kg (66 lbs): 20 mg every two weeks ≥30 kg (66 lbs): 40 mg every two weeks.
When it is not to be taken (Contraindications)
Why it is prescribed (Indications)
This medication is a tumor necrosis factor alpha (TNF alpha) inhibitor, prescribed for rheumatoid arthritis, crohn's disease (digestive tract inflammation), psoriatic arthritis, ulcerative colitis, plaque psoriasis, ankylosing spondylitis (spine infammation), and juvenile idiopathic arthritis (joint inflammation in children). It blocks the effect of TNF and thereby reduces the inflammation and its consequences in the joints and intestine.
Category C :
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Warnings and Precautions
It may cause serious infection, which leads to death, contact your healthcare provider immediately if you have any signs of infection such as fever, cough, or flu-like symptoms.
Perform lab test for tuberculosis before treatment. Monitor every patient for active tuberculosis while taking this medication.
Tuberculosis treatment should be given prior to this medication.
In some patients it may develop cancer like lymphoma.
Caution should be exercised in patients with cancer, multiple sclerosis, heart disease, during pregnancy and breastfeeding.
Refrigerate at 36°F to 46°F (2°C to 8°C) in an airtight container. Do not freeze. Do not use if frozen even if it has been thawed. When traveling, store HUMIRA in a cool carrier with an ice pack. Protect from light.